查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594130

偏頭痛藥物市場：依治療層級、治療類型、給藥途徑、分佈 - 全球預測 2025-2030

Migraine Drugs Market by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots), Treatment Type (Abortive, Preventive), Route of Administration, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年偏頭痛治療藥物市場價值為47.4億美元，預計到2024年將達到54.8億美元，複合年成長率為15.83%，預計到2030年將達到132.6億美元。

偏頭痛藥物市場範圍包括用於治療急性和慢性偏頭痛的藥物，其應用範圍從預防到流產治療。該市場的促進因素是解決影響全球生產力和生活品質的各種神經病變的需求。曲坦類、降鈣素基因相關胜肽抑制劑和非處方藥等處方藥佔其應用的大部分，最終用途是醫療機構、藥房和個別患者。偏頭痛發病率的增加、藥物配方的進步以及患者和醫療保健專業人員意識的提高對市場成長產生了重大影響。世界人口老化和不斷上升的壓力水平進一步推動了需求，為市場相關人員提供了創新解決方案以滿足這些人口統計數據的機會。特別是，個人化醫療和非侵入性遞送機制的發展提供了有利的途徑。然而，它們受到高昂的藥物成本、潛在副作用和嚴格的監管核准流程的限制，使得市場進入和擴張具有挑戰性。此外，傳統和非治療方法的存在治療方法減少需求。也就是說，對生物製藥、生物相似藥和數位治療解決方案的探索，以及針對個體基因譜量身定做的精準醫學方法的廣泛研究，為我們展示的創新提供了肥沃的土壤。市場的特點是競爭激烈，需要不斷的研發來保持競爭優勢並滿足不斷變化的消費者期望。企業應專注於建立策略夥伴關係關係，以獲取新技術並開拓開拓的市場，特別是在醫療基礎設施不斷擴張的新興國家。此外，您可以透過投資宣傳宣傳活動，向患者宣傳新治療方法並管理偏頭痛誘因。總體而言，保持敏捷性並回應監管變化和技術進步對於應對複雜的市場條件和充分利用成長潛力至關重要。

主要市場統計
基準年[2023] 47.4億美元
預測年份 [2024] 54.8億美元
預測年份 [2030] 132.6億美元
複合年成長率（%） 15.83%

市場動態：揭示快速發展的偏頭痛藥物市場的關鍵市場洞察

供需的動態交互作用正在改變偏頭痛藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 偏頭痛發生率增加和新藥上市
    • 女性人口增加和菸草消費量增加
    • 電神經刺激設備等醫療設施的進步
  • 市場限制因素
    • 與偏頭痛藥物相關的副作用
  • 市場機會
    • 偏頭痛藥物支持報銷政策
    • 增加製藥領域的合作和夥伴關係計劃
  • 市場挑戰
    • 替代療法的可用性和監管挑戰

波特五力：駕馭偏頭痛藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對偏頭痛藥物市場的影響

外部宏觀環境因素在塑造偏頭痛治療藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解偏頭痛治療藥物市場的競爭狀況

對偏頭痛治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 偏頭痛藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估偏頭痛治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪偏頭痛治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，偏頭痛治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 偏頭痛發生率增加和新藥上市
      • 女性人口增加和菸草消費量增加
      • 電神經刺激設備等醫療設施的進步
    • 抑制因素
      • 與偏頭痛藥物相關的副作用
    • 機會
      • 偏頭痛藥物補充報銷政策
      • 增加製藥領域的合作和夥伴關係計劃
    • 任務
      • 替代療法的可用性和監管挑戰
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級分類的偏頭痛治療藥物市場

  • 抗噁心藥
    • 氯丙嗪
    • 甲氧氯普胺
    • 琴酒
  • 抗高血壓藥
    • Β 受體阻斷劑藥
    • 鈣離子通道阻斷劑
  • 麥角
    • Dihydroergotamine
    • 麥角胺
    • 拉斯米迪坦
  • 鴉片類藥物
    • 奧施康定
    • 哌可賽特
    • 維柯丁
  • 止痛藥
    • 阿斯匹靈
    • Ibuprofen
  • 曲普坦
    • Rizatriptan
    • Sumatriptan

第7章依治療類型分類的偏頭痛治療藥物市場

  • 取消
  • 預防

第8章偏頭痛治療藥物市場：依給藥途徑

  • 可注射的
  • 鼻噴劑
  • 口服

第9章 偏頭痛治療藥物市場經銷商

  • 醫院附設藥房
  • 網路藥房
  • 零售藥房

第10章美洲偏頭痛藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章：亞太偏頭痛藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲偏頭痛藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Aegis Therapeutics, LLC
  • Alder Biopharmaceuticals, Inc.
  • Allergan Inc. by AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Biohaven, Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • GlaxoSmithKline Plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd
Product Code: MRR-036C5CF3A820

The Migraine Drugs Market was valued at USD 4.74 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 15.83%, to USD 13.26 billion by 2030.

The scope of the migraine drugs market encompasses medications developed to treat acute and chronic migraines, with applications spanning preventive and abortive treatments. This market is driven by the necessity to address a widespread neurological disorder impacting productivity and quality of life globally. Prescription drugs such as triptans, CGRP inhibitors, and over-the-counter medications form a significant part of its application scope, while the end-use spans healthcare settings, pharmacies, and individual patients. The market's growth is majorly influenced by the increasing prevalence of migraines, advancements in drug formulations, and rising awareness amongst patients and healthcare professionals. An aging population and increased stress levels globally further bolster demand, presenting opportunities for market players to innovate solutions catering to these demographics. Notably, personalized medicine and the development of non-invasive delivery mechanisms offer lucrative avenues. However, the market faces limitations due to high drug costs, potential side effects, and stringent regulatory approval processes which pose challenges to market entry and expansion. Furthermore, the presence of traditional and non-medical treatment alternatives can dilute demand. Nevertheless, the exploration of biologic drugs, biosimilars, and digital therapeutic solutions presents fertile ground for innovation, alongside conducting extensive research on precision medicine approaches tailored to individual genetic profiles. The market is characterized by intense competition, necessitating continuous research and development to maintain competitive advantage and meet evolving consumer expectations. Companies should focus on forming strategic partnerships to access new technologies and explore untapped markets, particularly in emerging economies where healthcare infrastructure is expanding. Additionally, investing in awareness campaigns to educate patients about new treatments and managing migraine triggers can enhance market presence. Overall, staying agile and responsive to regulatory shifts and technological advancements will be critical in navigating the complex landscape of the migraine drugs market and harnessing growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 4.74 billion
Estimated Year [2024] USD 5.48 billion
Forecast Year [2030] USD 13.26 billion
CAGR (%) 15.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Migraine Drugs Market

The Migraine Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of migraines and launch of new drugs
    • Rise in female population and increase in cigarette consumption
    • Advancements in healthcare facilities such as electrical nerve stimulation devices
  • Market Restraints
    • Side effects associated with migraine drugs
  • Market Opportunities
    • Supportive reimbursement policies for migraine medications
    • Increased programmes of collaboration and partnership in the pharmaceutical sector
  • Market Challenges
    • Availability of alternative therapies and regulatory challenges

Porter's Five Forces: A Strategic Tool for Navigating the Migraine Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Migraine Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Migraine Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Migraine Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Migraine Drugs Market

A detailed market share analysis in the Migraine Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Migraine Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Migraine Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Migraine Drugs Market

A strategic analysis of the Migraine Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Migraine Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aegis Therapeutics, LLC, Alder Biopharmaceuticals, Inc., Allergan Inc. by AbbVie Inc., Amgen, Inc., AstraZeneca Plc, Biohaven, Ltd, Eisai Co., Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, H. Lundbeck A/S, Johnson & Johnson Services, Inc., Merck & Co. Inc., Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Migraine Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan.
  • Based on Treatment Type, market is studied across Abortive and Preventive.
  • Based on Route of Administration, market is studied across Injectable, Nasal Spray, and Oral.
  • Based on Distribution, market is studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of migraines and launch of new drugs
      • 5.1.1.2. Rise in female population and increase in cigarette consumption
      • 5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with migraine drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive reimbursement policies for migraine medications
      • 5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative therapies and regulatory challenges
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Migraine Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Anti-Nausea Drug
    • 6.2.1. Chlorpromazine
    • 6.2.2. Metoclopramide
    • 6.2.3. Prochlorperazine
  • 6.3. Blood Pressure Lowering Medication
    • 6.3.1. Beta-Blocker
    • 6.3.2. Calcium Channel Blocker
  • 6.4. Ergots
    • 6.4.1. Dihydroergotamines
    • 6.4.2. Ergotamine
    • 6.4.3. Lasmiditan
  • 6.5. Opioid Medication
    • 6.5.1. OxyContin
    • 6.5.2. Percocet
    • 6.5.3. Vicodin
  • 6.6. Pain Reliever
    • 6.6.1. Aspirin
    • 6.6.2. Ibuprofen
  • 6.7. Triptans
    • 6.7.1. Rizatriptan
    • 6.7.2. Sumatriptan

7. Migraine Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Abortive
  • 7.3. Preventive

8. Migraine Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Nasal Spray
  • 8.4. Oral

9. Migraine Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospitals Based Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Migraine Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Migraine Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Migraine Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aegis Therapeutics, LLC
  • 3. Alder Biopharmaceuticals, Inc.
  • 4. Allergan Inc. by AbbVie Inc.
  • 5. Amgen, Inc.
  • 6. AstraZeneca Plc
  • 7. Biohaven, Ltd
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Endo International Plc
  • 11. GlaxoSmithKline Plc
  • 12. H. Lundbeck A/S
  • 13. Johnson & Johnson Services, Inc.
  • 14. Merck & Co. Inc.
  • 15. Pfizer Inc.
  • 16. Sanofi SA
  • 17. Teva Pharmaceuticals Industries Ltd

LIST OF FIGURES

  • FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MIGRAINE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MIL